We are live on ! Find out more

INVO Fertility Inc

IVF

Market cap $2.91M

2.44 USD

+0.09

3.83%

At close Updated Nov 10, 10:04 AM EST

1 day

3.83%

5 days

25.77%

1 month

-15.86%

3 months

-41.35%

6 months

-62.11%

Year to date

-86.44%

1 year

-97.23%

5 years

-100%

10 years

-100%

About: INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.

Employees: 46

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 85.7%

Negative 0%

INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable

SARASOTA, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a fertility services company focused on expanding access to care, today announced a partnership with PatientFi to offer affordable patient financing options designed to help more individuals and couples move forward with fertility treatment.

INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable

INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026

SARASOTA, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, announced today that it will effect a 1-for-4 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on October 30, 2026. Commencing with the opening of trading on The Nasdaq Capital Market on October 30, 2026, the Company's common stock will trade on a post-split basis under the same trading symbol, “IVF”.

INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026

INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference

SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that Gretchen Collins, M.D.

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

INVO Fertility Stock Surges Following Q2 Earnings Beat

Shares of INVO Fertility Inc. (NASDAQ:IVF) are surging Monday afternoon after the healthcare fertility company reported second-quarter financial results that significantly outperformed Wall Street expectations on bottom-line earnings.

INVO Fertility Stock Surges Following Q2 Earnings Beat

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Why INVO Fertility Stock Is Surging Friday Afternoon

INVO Fertility Inc (NASDAQ:IVF) shares are surging Friday afternoon following a pair of key operational and regulatory milestones disclosed in a new SEC Form 8-K filing. Here's what investors need to know.

Why INVO Fertility Stock Is Surging Friday Afternoon

INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet

INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q

SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice relates to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "10-K"), and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "10-Q").

INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q

See News Rankings

Price charts implemented using Lightweight Charts™